| 2025-11-13 |
详情>>
股本变动：
变动后总股本12028.47万股
|
| 2025-11-13 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-0.55美元,归母净利润-7787.2万美元,同比去年增长-3.37%
|
| 2025-08-07 |
详情>>
业绩披露：
2025年中报每股收益-0.45美元,归母净利润-5229.3万美元,同比去年增长-2.61%
|
| 2025-06-13 |
详情>>
内部人交易：
Nash Duane股份增加20000.00股
|
| 2025-05-15 |
详情>>
业绩披露：
2025年一季报每股收益-0.25美元,归母净利润-2547.3万美元,同比去年增长13.90%
|
| 2025-04-22 |
股东大会：
将于2025-06-04召开股东大会
会议内容 ▼▲
- 1.To elect Dr. Neermann, Ms. Tamar Howson, and Mr. Barclay Phillips as Class II Directors to serve until our 2028 annual meeting of stockholders and until their successors are duly elected and qualified.
2.To approve an amendment to the Immunic, Inc. 2019 Omnibus Equity Incentive Plan, as Amended (the “Existing 2019 Omnibus Plan”), to increase the number of shares of common stock authorized for issuance by 7,000,000 shares to a total of 26,448,871 shares.
3.To ratify the appointment of Baker Tilly US, LLP (“Baker Tilly”) as our independent registered public accounting firm for the fiscal year ending December 31, 2025.
4.To transact other business that may properly come before the annual meeting.
|
| 2025-03-31 |
详情>>
业绩披露：
2024年年报每股收益-1美元,归母净利润-1.01亿美元,同比去年增长-7.37%
|
| 2024-11-07 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-0.75美元,归母净利润-7533.2万美元,同比去年增长-4.57%
|
| 2024-11-07 |
财报披露：
美东时间 2024-11-07 盘前发布财报
|
| 2024-08-08 |
详情>>
业绩披露：
2024年中报每股收益-0.51美元,归母净利润-5096.4万美元,同比去年增长-3.44%
|
| 2024-05-08 |
详情>>
业绩披露：
2024年一季报每股收益-0.3美元,归母净利润-2958.4万美元,同比去年增长-17.06%
|
| 2024-04-23 |
股东大会：
将于2024-06-11召开股东大会
会议内容 ▼▲
- 1.To elect Dr. Daniel Vitt and Dr. Duane Nash as Class I Directors to serve until our 2027 annual meeting of stockholders and until their successors are duly elected and qualified.
2.To ratify the appointment of Baker Tilly US, LLP (“Baker Tilly”) as our independent registered public accounting firm for the fiscal year ending December 31, 2024.
3.To approve, by non-binding advisory vote, the resolution approving named executive officer compensation.
4.To transact other business that may properly come before the annual meeting.
|
| 2024-02-22 |
详情>>
业绩披露：
2023年年报每股收益-2.11美元,归母净利润-9361.2万美元,同比去年增长22.25%
|
| 2024-02-05 |
股东大会：
将于2024-03-04召开股东大会
会议内容 ▼▲
- 1.To approve an amendment of Immunic’s amended and restated certificate of incorporation (the “Amended and Restated Certificate of Incorporation”) to increase the total number of authorized shares of common stock, $0.0001 par value per share (the “Common Stock”), from 130,000,000 shares to 500,000,000;
2.To approve an amendment to the Immunic, Inc. Amended and Restated 2021 Employee Stock Purchase Plan (the “2021 Employee Stock Purchase Plan”) to increase the number of shares of Common Stock reserved for delivery under the Employee Stock Purchase Plan by 1,000,000 shares to a total of 1,200,000 shares;
3.To approve an amendment to the Immunic, Inc. 2019 Omnibus Equity Incentive Plan, as Amended (the “Existing 2019 Omnibus Plan”), to increase the number of shares of common stock authorized for issuance by 9,100,000 shares to a total of 19,448,871 shares;
4.To approve the repricing of certain outstanding stock options;
5.To transact other business that may properly come before the Special Meeting.
|
| 2023-11-14 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-1.63美元,归母净利润-7204万美元,同比去年增长-12.68%
|
| 2023-08-03 |
详情>>
业绩披露：
2023年中报每股收益-1.12美元,归母净利润-4927.1万美元,同比去年增长-15.36%
|
| 2023-05-01 |
股东大会：
将于2023-06-28召开股东大会
会议内容 ▼▲
- 1.To elect Dr. Richard Rudick and Maria Tornsen as Class III Directors to serve until our 2026 annual meeting of stockholders and until their successors are duly elected and qualified.
2.To ratify the appointment of Baker Tilly US, LLP (“Baker Tilly”) as our independent registered public accounting firm for the fiscal year ending December 31, 2023.
3.To approve amendments to our 2019 Omnibus Plan to (i) increase the number of common stock authorized for issuance by 4,440,000 shares to a total of 10,348,871 shares, and (ii) remove the "evergreen" provision pursuant to which the aggregate number of shares authorized for issuance automatically increases each year.
4.To transact other business that may properly come before the annual meeting.
|
| 2022-06-02 |
复牌提示：
2022-06-02 09:30:38 停牌，复牌日期 2022-06-02 09:35:38
|
| 2022-04-27 |
股东大会：
将于2022-06-15召开股东大会
会议内容 ▼▲
- 1.To elect Ms. Tamar Howson, Dr. Jrg Neermann and Mr. Barclay Phillips as Class II Directors to serve until our 2025 annual meeting of stockholders and until their successors are duly elected and qualified.
2.To ratify the appointment of Baker Tilly Virchow Krause, LLP (“Baker Tilly”) as our independent registered public accounting firm for the fiscal year ending December 31, 2022.
3.To transact other business that may properly come before the annual meeting.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-27 |
股东大会：
将于2021-06-10召开股东大会
会议内容 ▼▲
- 1.To elect Dr. Daniel Vitt and Dr. Duane Nash as Class I Directors to serve until our 2024 annual meeting of stockholders and until their successors are duly elected and qualified.
2.To approve, by non-binding advisory vote, the resolution approving named executive officer compensation.
3.To approve, by non-binding advisory vote, the frequency of future non-binding advisory votes on resolutions approving future named executive officer compensation.
4.To approve our 2021 Employee Stock Purchase Plan.
5.To ratify the appointment of Baker Tilly Virchow Krause, LLP (“Baker Tilly”) as our independent registered public accounting firm for the fiscal year ending December 31, 2021.
6.To transact other business that may properly come before the annual meeting.
|
| 2020-04-29 |
股东大会：
将于2020-06-02召开股东大会
会议内容 ▼▲
- 1.To elect Dr. Vincent Ossipow and Mr. Jan Van den Bossche as Class III Directors to serve until our 2023 annual meeting of stockholders and until their successors are duly elected and qualified.
2.To ratify the appointment of Baker Tilly Virchow Krause, LLP (“Baker Tilly”) as our independent registered public accounting firm for the fiscal year ending December 31, 2020.
3.To transact other business that may properly come before the annual meeting.
|
| 2019-06-18 |
股东大会：
将于2019-07-16召开股东大会
会议内容 ▼▲
- 1.To elect Dr. Jrg Neermann as a Class I Director to serve until our 2022 annual meeting of stockholders and until his successor is duly elected and qualified.
2.To ratify the appointment of Baker Tilly Virchow Krause, LLP (“Baker Tilly”) as our independent registered public accounting firm for the fiscal year ending December 31, 2019.
3.To approve the amendment and restatement of our Amended and Restated Certificate of Incorporation.
4.To approve our 2019 Omnibus Plan.
5.To transact other business that may properly come before the annual meeting.
|
| 2019-04-15 |
详情>>
拆分方案：
每40.0000合并分成1.0000股
|
| 2018-04-12 |
股东大会：
将于2018-05-23召开股东大会
会议内容 ▼▲
- (1) To elect as Class I directors the three nominees named in the accompanying proxy statement to serve until our 2021 annual meeting of stockholders and until their respective successors are duly elected and qualified.
(2) To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018.
(3) To transact other business that may properly come before the annual meeting.
|
| 2017-04-11 |
股东大会：
将于2017-05-23召开股东大会
会议内容 ▼▲
- 1.To elect as Class III directors the four nominees named in the accompanying proxy statement to serve until our 2020 annual meeting of stockholders and until their respective successors are duly elected and qualified.
2.To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2017.
3.To transact other business that may properly come before the annual meeting.
|
| 2016-04-14 |
股东大会：
将于2016-05-24召开股东大会
会议内容 ▼▲
- 1.To elect as Class II directors the three nominees named in the accompanying proxy statement to serve until our 2019 annual meeting of stockholders and until their respective successors are duly elected and qualified.
2.To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2016.
3.To transact other business that may properly come before the annual meeting.
|
| 2015-10-07 |
股东大会：
将于2015-11-17召开股东大会
会议内容 ▼▲
- (1) To elect as Class I directors the three nominees named in the accompanying proxy statement to serve until our 2018 annual meeting of stockholders and until their respective successors are duly elected and qualified.
(2) To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2015.
(3) To transact other business that may properly come before the annual meeting.
|